Comparison of 2-Weekly Versus 4-Weekly Durvalumab Consolidation for Locally Advanced NSCLC Treated With Chemoradiotherapy: A Brief Report

INTRODUCTION: Durvalumab 10 mg/kg every 2 weeks for 1 year after chemoradiation has improved overall survival (OS) in unresectable stage III NSCLC. Subsequently, a 20 mg/kg 4-weekly regimen was approved. The study goal was to compare the efficacy and toxicity of the two regimens. METHODS: All patien...

Descripción completa

Detalles Bibliográficos
Autores principales: Denault, Marie-Hélène, Kuang, Shelley, Shokoohi, Aria, Leung, Bonnie, Liu, Mitchell, Berthelet, Eric, Laskin, Janessa, Sun, Sophie, Zhang, Tina, Melosky, Barbara, Ho, Cheryl
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2022
Materias:
Brief Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9046443/
https://www.ncbi.nlm.nih.gov/pubmed/35498385
http://dx.doi.org/10.1016/j.jtocrr.2022.100316

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9046443/
https://www.ncbi.nlm.nih.gov/pubmed/35498385
http://dx.doi.org/10.1016/j.jtocrr.2022.100316

Ejemplares similares